ent because patients and healthy subjects told us blooding drawing was a kind of noninvasive test.So it was not necessary to write informed consent.Before drawing blood of every experiment subject,we told them the purpose of drawing blood, we also paid some money for the subjects. So the experiment subjects were willing to attend our experiment and gave verbal informed consent. The ethic committee approved this consent procedure. Clinical and laboratory data were collected from all subjects. 1 Small-Size Endothelial Microparticles in CAD Isolation and measurement of small-size endothelial microparticles Microparticles were isolated using a single protocol to avoid variations in pre-analytical procedures. Blood samples were obtained by venipuncture and transferred to blue-top vacutainer tubes containing sodium citrate. 
Within 1 hour of sampling, whole blood samples were centrifuged at 1500 g for 10 min to prepare platelet-rich plasma and then centrifuged again at 13,000 g for 10 min to obtain platelet- free plasma. Thereafter, samples were stored at 220uC for 1 week and then at 280uC until analyzed. Microparticle levels were not affected by thawing the plasma stocks once. PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19664521 For the SEMPs assay, platelet-poor plasma was incubated with both of the following fluorescent monoclonal antibodies: phycoerythrin -labeled anti-CD31 and PElabeled anti-CD62E. Thereafter, the samples were incubated at room temperature for 20 min, diluted with 1 ml of phosphate-buffered saline, and analyzed by flow cytometry. For specific delineation of CD31+ endothelial microparticles, and not of platelet-derived CD31+ microparticles, CD42b2 microparticles were analyzed in platelet-free plasma. For flow cytometry analysis of SEMPs, a signal MedChemExpress (S)-(-)-Blebbistatin intensity threshold of 35,000 was used and standard beads were used for calibration. Forward scatter intensity versus side scatter intensity dot plots were generated by gating on microparticles, followed by one- or two-color fluorescence histograms. Accuri C6 software was used to quantify the absolute numbers of SEMPs per unit of sample. In all measurements, an isotype control antibody was used as the negative control. SEMPs were defined as CD31+/ CD422 or CD62E+. Values are reported as counts per ml of peripheral blood. The laboratory personnel who performed these assays were blinded to all clinical data and the study participants. distributed. Differences between groups were analyzed using the Student’s test. The chi-square test was used to compare quantitative and categorical variables. Multiple linear regression analysis was used to determine whether various factors were independently associated with the percentage of CD62E+ SEMPs. The ability of the percentage of CD62E+ SEMPs to predict CAD was determined using a receiver operating characteristic curve. The area under the ROC curve ) measured the accuracy of the diagnostic test. Values close to 0.5 indicated failure of the test, whereas values close to 1 indicated that the accuracy of the test was virtually perfect. Therefore, Our study is the first time to show CD62E+SEMPs could be a new informative biomarker to monitor endothelial dysfunction in CAD. The presence of CD62E+ endothelial microparticles is an indication of endothelial activation; therefore, the results of the present study suggested that endothelial activation participates in the pathogenesis of CAD. The percentage of CD62E+ SEMPs is likely to be a biomarker for endothelial function in CAD. Due to the limitation